Overview


According to FutureWise analysis the market for chronic pain management drugs in 2023 is US$ 100.03 billion, and is expected to reach US$ 177.34 billion by 2031 at a CAGR of 7.40%.

Pain is an unpleasant sensory and emotional sensation caused by tissue disease or tissue damage. Multiple sclerosis, osteoarthritis and stomach ulcers can cause pain. Acute pain can last for a short time, but chronic pain can last for a long time. Acute pain may be short-term or long-lasting. Chronic pain can be caused by nerve damage, old bone and joint conditions, injury, or nerve damage. There are many drugs that can be used to treat pain caused by inflammation due to tissue damage, chemical agents/pathogens (nociceptive) or nerve damage (neuropathic). Many drugs work by binding to proteins on cell membranes, affecting biochemical processes and other ways. The pain management drugs work by blocking discomfort-causing symptoms and pharmacologically acting on pain receptors. The medications can relieve the pain caused by various health conditions, including osteoarthritis and chronic arthritis, diabetes neuropathy, multiple Sclerosis, multiple sclerosis, cancer, and diabetic neuropathy. They also work through different physiological functions. Medical advancements in recent years have allowed for the development of new combinations and better drug delivery methods that offer pain relief. For severe to moderate pain conditions, such as back pain, neck and cancer pain, pain management drugs can be prescribed. The low supply of pain management drugs is making the market highly profitable. Market growth is being driven by the introduction of generic pain management drugs that are more effective in different dosage forms by drug manufacturers. These medications are primarily used to treat chronic pain, which is one of the most common pain conditions. Medical management of pain disorders is individual and highly dependent upon the symptoms of each patient. A tissue injury or disease can cause pain, which is a distressing sensory and emotional sensation. Pain can also be caused by multiple conditions, such as osteoarthritis and multiple sclerosis, chronic pain, diabetes neuropathy, stomach ulcers, fibromyalgia, multiple sclerosis, multiple sclerosis, multiple sclerosis, chronic inflammation, multiple sclerosis, multiple sclerosis, cancer, and diabetic neuropathy. There are many types of pain, ranging from acute short-term pain to chronic long-term pain. Acute pain may be short-term and last for a few minutes, weeks, or months. Chronic pain can be caused by injury, ageing, nerve loss, and damaged bones and joints. There are many options available to treat pain caused by inflammation due to tissue damage, chemical agents/pathogens (nociceptive) or nerve damage (neuropathic). Many drugs work by binding to proteins on cell membranes, affecting biochemical processes and other ways.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Chronic Pain Management Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Chronic Pain Management Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Pfizer Inc
  • Depomed Inc
  • Endo International Plc
  • Purdue Pharma L.P.
  • Novartis AG
  • AstraZeneca plc
  • Johnsonand Johnson
  • Merck and Co
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Teva Pharmaceutical

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Anticonvulsants
  • Antidepressants
  • Anesthetics
  • Non-Steroidal Anti-inflammatory Drugs
  • Opioids
  • Non-narcotic Anagesic
  • Antimigraine Agents

By Prescription Type

  • Prescribed
  • Over The counter

By Distribution Channel

  • Hospital Pharmacy
  • Drug Store
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Chronic Pain Management Drugs Market By Product Type, By Prescription Type, By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Chronic Pain Management Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Chronic Pain Management Drugs Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Chronic Pain Management Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Chronic Pain Management Drugs Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anticonvulsants
        2. Antidepressants
        3. Anesthetics
        4. Non-Steroidal Anti-inflammatory Drugs
        5. Opioids
        6. Non-narcotic Anagesic
        7. Antimigraine Agents

  • 8.   Chronic Pain Management Drugs Market, By Prescription Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Prescribed
        2. Over The counter

  • 9.   Chronic Pain Management Drugs Market,By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Drug Store
        3. Retail Pharmacy
        4. Online Pharmacy

  • 10.   North America Chronic Pain Management Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Chronic Pain Management Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Chronic Pain Management Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Chronic Pain Management Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Pfizer Inc
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Depomed Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Endo International Plc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
           4. Purdue Pharma L.P.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. AstraZeneca plc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Johnson & Johnson
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Merck Co
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Abbott Laboratories
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. GlaxoSmithKline plc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Teva Pharmaceutical
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients